- Results from XLRS study support general safety and tolerability of AGTC’s gene delivery platform but did not demonstrate signs of clinical activity at interim six-month time point - - AGTC to regain rights to five clinical and preclinical development programs; Biogen terminates collaboration
GAINESVILLE, Fla. and CAMBRIDGE, Mass. , Nov. 08, 2018 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced
GAINESVILLE, Fla. and CAMBRIDGE, Mass. , Nov. 01, 2018 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced that
GAINESVILLE, Fla. and CAMBRIDGE, Mass. , Sept. 27, 2018 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced
GAINESVILLE, Fla. and CAMBRIDGE, Mass. , Sept. 24, 2018 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (NASDAQ: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced it
GAINESVILLE, Fla. and CAMBRIDGE, Mass. , Sept. 10, 2018 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced
GAINESVILLE, Fla. and CAMBRIDGE, Mass. , Aug. 30, 2018 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced that
GAINESVILLE, Fla. and CAMBRIDGE, Mass. , Aug. 08, 2018 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (NASDAQ: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced that
Company Provides Pipeline Enrollment Update for Clinical Trials in Inherited Retinal Diseases GAINESVILLE, Fla. and CAMBRIDGE, Mass. , July 23, 2018 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (NASDAQ:AGTC), a biotechnology company conducting human clinical trials of
20+ Year Medical Affairs and Ophthalmology Veteran, Lanita C. Scott , M.D., Appointed as Vice President of Clinical Research and Medical Affairs Karen M. Carroll, RN , Named Vice President of Clinical Development Operations GAINESVILLE, Fla. and CAMBRIDGE, Mass.
